Running Head: Economics in End Stage Renal Disease
The article “End Stage Renal Disease economics and the balance of treatment modalities”(sullivan,2010) expounds on the major reimbursement mechanisms for the treatment of End Stage Renal Disease (ESRD) from the economic point of view. He broadly examines the economic consequences of Medicare’s provisions that are dedicated to treating ESRD. Additionally, he assesses the monetary and health impacts of the different treatment types of ESRD while at the same time evaluating the ethical implications of the other treatment options that are based on cost evaluation. The paper presents a critical analysis of the article with emphasis on the major issues that the author has addressed.
The Major Reimbursement Mechanisms
In the article, Sullivan (2010) contends that many articles have emerged arguing for the economic benefits of peritoneal dialysis (PD) for patients who suffer from ESRD rather than the in-centre hemodialysis. Relatively, many have argued that PD is the ideal cheaper therapy for the treatment of such a disease. However, an increasing number of patients are still referred for in-centre hemodialysis. In order to control the rising costs that have been caused by this trend, the author then suggests that the best way is by referring many patients for PD rather than the dialysis procedure. ( p. 45).
ESRD presents at the most chronic stage of kidney disease (stage 5) which represents a complete renal failure. At this stage, the body lacks the ability to remove excess fluids and toxins this threatens the life of the patient. Up to date, there is no known cure for the end stage renal disease. Patients who suffer from this will need kidney transplantation or dialysis in order to survive (Sullivan, 2010, p. 45).Without immediate treatment the patient suffers from uremia which is a fatal condition. The main cause of ESRD is diabetes and hypertension.
There are three treatment options for ESRD...